Results 201 to 210 of about 16,960 (244)
Some of the next articles are maybe not open access.
International Journal of Cardiology
BACKGROUND The guidelines recommend the initiation or up-titration of heart failure (HF) treatments following an HF hospitalization; however, concerns about adverse events may limit the use of mineralocorticoid receptor antagonists (MRAs).
M. Kobayashi +7 more
semanticscholar +1 more source
BACKGROUND The guidelines recommend the initiation or up-titration of heart failure (HF) treatments following an HF hospitalization; however, concerns about adverse events may limit the use of mineralocorticoid receptor antagonists (MRAs).
M. Kobayashi +7 more
semanticscholar +1 more source
European Journal of Ophthalmology, 2022
Purpose To evaluate retinal and choriocapillary vessel density (VD) changes in patients with chronic central serous chorioretinopathy (CSC) treated with half-fluence verteporfin photodynamic therapy (vPDT) or eplerenone, using optical coherence ...
Lidia Clemente +5 more
semanticscholar +1 more source
Purpose To evaluate retinal and choriocapillary vessel density (VD) changes in patients with chronic central serous chorioretinopathy (CSC) treated with half-fluence verteporfin photodynamic therapy (vPDT) or eplerenone, using optical coherence ...
Lidia Clemente +5 more
semanticscholar +1 more source
Cellular Signalling
BACKGROUND Eplerenone is a selective aldosterone receptor blocker that is effective in preventing the progression of chroinic kidney disease (CKD). However, its mechanism and role in CKD pregnancy still remain uncertain.
Wenping Zhou +10 more
semanticscholar +1 more source
BACKGROUND Eplerenone is a selective aldosterone receptor blocker that is effective in preventing the progression of chroinic kidney disease (CKD). However, its mechanism and role in CKD pregnancy still remain uncertain.
Wenping Zhou +10 more
semanticscholar +1 more source
Clinical science
Excessive activation of the mineralocorticoid receptor (MR) is implicated in cardiovascular and renal disease. Decreasing MR activation with MR antagonists (MRA) is effective to slow chronic kidney disease (CKD) progression and its cardiovascular ...
R. Palacios-Ramírez +8 more
semanticscholar +1 more source
Excessive activation of the mineralocorticoid receptor (MR) is implicated in cardiovascular and renal disease. Decreasing MR activation with MR antagonists (MRA) is effective to slow chronic kidney disease (CKD) progression and its cardiovascular ...
R. Palacios-Ramírez +8 more
semanticscholar +1 more source
Expert Opinion on Pharmacotherapy, 2004
Appreciation of the role of aldosterone in cardiovascular and renal disease has increased in the last 50 years. The use of spironolactone was limited by adverse sexual effects, including gynaecomastia. Eplerenone is a newer aldosterone antagonist that is much more selective, with minimal affinity for progesterone and androgenic receptors; therefore ...
openaire +2 more sources
Appreciation of the role of aldosterone in cardiovascular and renal disease has increased in the last 50 years. The use of spironolactone was limited by adverse sexual effects, including gynaecomastia. Eplerenone is a newer aldosterone antagonist that is much more selective, with minimal affinity for progesterone and androgenic receptors; therefore ...
openaire +2 more sources
Pharmacotherapy, 2021
Mineralocorticoid receptor antagonist (MRA) when combined with either angiotensin‐converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may provide additional benefits of cardiovascular and kidney disease risk reduction in patients
J. An, F. Niu, J. Sim
semanticscholar +1 more source
Mineralocorticoid receptor antagonist (MRA) when combined with either angiotensin‐converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may provide additional benefits of cardiovascular and kidney disease risk reduction in patients
J. An, F. Niu, J. Sim
semanticscholar +1 more source
Current opinion in investigational drugs (London, England : 2000), 2003
Pharmacia Corp (formerly GD Searle & Co) is developing eplerenone, an aldosterone receptor antagonist, as a potential treatment for congestive heart failure and systemic hypertension. The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on ...
Liew, Danny +2 more
openaire +1 more source
Pharmacia Corp (formerly GD Searle & Co) is developing eplerenone, an aldosterone receptor antagonist, as a potential treatment for congestive heart failure and systemic hypertension. The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on ...
Liew, Danny +2 more
openaire +1 more source
▼Eplerenone after myocardial infarction?
Drug and Therapeutics Bulletin, 2008Each year in the UK, an estimated 50,000 patients develop major left ventricular systolic dysfunction (LVSD) and heart failure following a myocardial infarct.1 Such patients have a particularly poor prognosis.2 ▼Eplerenone (Inspra – Pfizer) is an aldosterone-receptor antagonist for patients who have LVSD and heart failure following a recent myocardial ...
openaire +2 more sources